Pomerantz Law Firm Investigates Claims Against ClearPoint Neuro Following Stock Drop
The law firm of Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by ClearPoint Neuro, Inc. (NASDAQ: CLPT) and its officers following a significant drop in the company's stock price on September 29, 2026. This decline occurred after uniQure N.V., ClearPoint’s development partner, announced that their treatment for Huntington’s disease did not achieve statistical significance at 48 months. As a result, ClearPoint’s share price fell by $3.54 per share (or 23.12%) to close at $11.77. Pomerantz LLP is one of the leading firms in corporate and securities litigation and has recovered multimillion-dollar damages for class members in past cases.
Tickers: $CLPT
Topics: clinical trial results legal action stock price drop
Read the full article at PR Newswire
Part of the story Investor Alert: Pomerantz Law Firm Investigates Pasqal Holding SA for Potential Securities Fraud (5 articles)